(Reuters) – Pfizer Inc PFE.N said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.
The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE BNTX.O22UAy.F was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.
Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.
Moderna Inc MRNA.O on Monday released preliminary data for its vaccine, showing similar effectiveness.
